K

Kaohsiung Veterans General Hospital | Department of Allergy, Immunology and Rheumatology

Research site

(Unclaimed)

Location

No.386, Dazhong 1st Road Zuoying Dist., Kaohsiung City, Kaohsiung, Taiwan

Site insights

Top conditions

Top treatments

TAK-279

SHJ002

Sisunatovir

Hydroxyurea

PF-06700841

Ropeginterferon Alfa-2b

P1101

Anagrelide

Cyclophosphamide

Interferon

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 21 total trials

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque p...

Active, not recruiting

Plaque Psoriasis

Drug: Placebo

Drug: Apremilast

Locations recently updated

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoria...

Enrolling

Plaque Psoriasis

Drug: TAK-279

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance (SURPASS ET)

This is a Phase 3 open-label, multicenter, randomized, active-controlled study designed to compare the efficacy and safety and tolerability of P1101...

Active, not recruiting

Essential Thrombocythemia

Drug: Anagrelide

Biological: Ropeginterferon alfa-2b